NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
Updated: Feb 10
A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B). The dose escalation (Part A) of the study will evaluate the safety and tolerability of increasing doses of CC-95266 in a single administration to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of CC-95266 at the RP2D.
Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Multiple Locations
ClinicalTrials.gov Identifier: NCT04674813
Official Title: A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
First Posted : December 19, 2020
Click here for details on ClinicalTrials.gov
Click here for details on cancer.gov
CC-95266
Multi-center phase I of GPRC5D-Targeted CARs
Drug: CC-95266
Drug: Fludarabine
Drug: Cyclophosphamide
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: UT Southwestern Medical Center Dallas
Locations
United States, Alabama
United States, California
United States, Colorado
United States, Maryland
United States, Massachusetts
United States, New York
United States, Tennessee
United States, Texas
United States, Washington
Comments